AU715676B2
(en)
*
|
1993-03-12 |
2000-02-10 |
Merck Frosst Canada & Co. |
Use of inhibitors of cyclooxygenase in the treatment of neurodegenerative diseases
|
GB9420616D0
(en)
*
|
1994-10-12 |
1994-11-30 |
Merck Sharp & Dohme |
Method, compositions and use
|
US5840746A
(en)
*
|
1993-06-24 |
1998-11-24 |
Merck Frosst Canada, Inc. |
Use of inhibitors of cyclooxygenase in the treatment of neurodegenerative diseases
|
GB2294879A
(en)
*
|
1994-10-19 |
1996-05-15 |
Merck & Co Inc |
Cylcooxygenase-2 Inhibitors
|
CA2211320C
(en)
*
|
1995-01-31 |
2007-03-20 |
Merck Frosst Canada Inc. |
5-methanesulfonamido-3h-isobenzofuran-1-ones as inhibitors of cyclooxygenase-2
|
US5571825A
(en)
*
|
1995-03-31 |
1996-11-05 |
Warner-Lambert Company |
Method of selectively inhibiting prostaglandin G/H synthase-2
|
AU5886296A
(en)
|
1995-06-02 |
1996-12-18 |
G.D. Searle & Co. |
Heterocyclo substituted hydroxamic acid derivatives as cyclo oxygenase-2 and 5-lipoxygenase inhibitors
|
US6512121B2
(en)
|
1998-09-14 |
2003-01-28 |
G.D. Searle & Co. |
Heterocyclo substituted hydroxamic acid derivatives as cyclooxygenase-2 and 5-lipoxygenase inhibitors
|
US6515014B2
(en)
|
1995-06-02 |
2003-02-04 |
G. D. Searle & Co. |
Thiophene substituted hydroxamic acid derivatives as cyclooxygenase-2 and 5-lipoxygenase inhibitors
|
US5643933A
(en)
*
|
1995-06-02 |
1997-07-01 |
G. D. Searle & Co. |
Substituted sulfonylphenylheterocycles as cyclooxygenase-2 and 5-lipoxygenase inhibitors
|
JPH11507669A
(ja)
*
|
1995-06-12 |
1999-07-06 |
ジー.ディー.サール アンド カンパニー |
シクロオキシゲナーゼ−2インヒビターとロイコトリエンb▲下4▼受容体アンタゴニストの組合せによる炎症と炎症関連疾患の治療
|
CA2224517A1
(en)
*
|
1995-06-12 |
1996-12-27 |
G.D. Searle & Co. |
Compositions comprising a cyclooxygenase-2 inhibitor and a 5-lipoxygenase inhibitor
|
US5700816A
(en)
*
|
1995-06-12 |
1997-12-23 |
Isakson; Peter C. |
Treatment of inflammation and inflammation-related disorders with a combination of a cyclooxygenase-2 inhibitor and a leukotriene A4 hydrolase inhibitor
|
US5968974A
(en)
*
|
1995-07-19 |
1999-10-19 |
Merck & Co., Inc. |
Method of treating colonic adenomas
|
US6593361B2
(en)
|
1995-07-19 |
2003-07-15 |
Merck & Co Inc |
Method of treating colonic adenomas
|
JPH11510485A
(ja)
*
|
1995-07-21 |
1999-09-14 |
ニィコメド・オーストリア・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング |
酵素のシクロオキシゲナーゼiiの阻害剤としてのベンゼンスルホンアミドの誘導体
|
DE19533643A1
(de)
*
|
1995-09-12 |
1997-03-13 |
Nycomed Arzneimittel Gmbh |
Neue cyclische Derivate von Benzolsulfonamiden
|
JPH09176038A
(ja)
*
|
1995-09-18 |
1997-07-08 |
Hisamitsu Pharmaceut Co Inc |
抗炎症性アンチセンス薬物
|
CA2234633A1
(en)
*
|
1995-10-17 |
1997-04-24 |
G.D. Searle & Co. |
Method of detecting cyclooxygenase-2
|
ATE223732T1
(de)
|
1996-02-13 |
2002-09-15 |
Searle & Co |
Arzneimittelkombinationen mit immunosuppressiven wirkungen welche cyclooxygenase-2 inhibitoren und leukotrien lta4 hydrase-inhibitoren enthalten
|
DE69709069T2
(de)
|
1996-02-13 |
2002-07-04 |
Searle & Co |
Zusammensetzungen mit immunosuppressiven wirkungen, welche 5-lipoxygenase-inhibitoren und cyclooxygenase-2-inhibitoren enthalten
|
JP2000505445A
(ja)
|
1996-02-13 |
2000-05-09 |
ジー.ディー.サール アンド カンパニー |
シクロオキシゲナーゼ―2インヒビターとロイコトリエンb▲下4▼受容体アンタゴニストの投与の免疫抑制作用
|
PT892791E
(pt)
|
1996-04-12 |
2003-06-30 |
Searle & Co |
N-¬¬4-(5-metil-3-fenilisoxazol-4-il|fenil|sulfonil-propilamida e seu sal de sodio como pro-farmacos de inibidores de cox-2
|
US6677364B2
(en)
|
1998-04-20 |
2004-01-13 |
G.D. Searle & Co. |
Substituted sulfonylphenylheterocycles as cyclooxygenase-2 and 5-lipoxygenase inhibitors
|
US5939069A
(en)
|
1996-08-23 |
1999-08-17 |
University Of Florida |
Materials and methods for detection and treatment of immune system dysfunctions
|
IT1288123B1
(it)
|
1996-09-04 |
1998-09-10 |
Nicox Sa |
Uso di nitroderivati per l'incontinenza urinaria
|
IL128568A0
(en)
|
1996-10-15 |
2000-01-31 |
Searle & Co |
Use of cyclooxygenase-2 inhibitors for the manufacture of a medicament for the treatment and prevention of neoplasia
|
US5681842A
(en)
*
|
1996-11-08 |
1997-10-28 |
Abbott Laboratories |
Prostaglandin synthase-2 inhibitors
|
US5985930A
(en)
*
|
1996-11-21 |
1999-11-16 |
Pasinetti; Giulio M. |
Treatment of neurodegenerative conditions with nimesulide
|
ATA16597A
(de)
*
|
1997-02-03 |
1998-04-15 |
Nycomed Austria Gmbh |
Neue substituierte p-sulfonylaminobenzol- sulfonsäureamide
|
WO1998051667A1
(fr)
*
|
1997-05-16 |
1998-11-19 |
Chugai Seiyaku Kabushiki Kaisha |
Derives d'indole et derives de mono- et diazaindole
|
ES2138902B1
(es)
*
|
1997-05-19 |
2000-09-16 |
Salvat Lab Sa |
"5-ariltio-6-sulfonamido-3(2h)-benzofuranonas como inhibidores de la cox-2".
|
EP1015431B1
(de)
*
|
1997-09-12 |
2005-04-20 |
Merck Frosst Canada & Co. |
2-aminopyridine als inhibitoren von cyclooxygenase-2
|
US6004950A
(en)
*
|
1997-09-12 |
1999-12-21 |
Merck Frosst Canada, Inc. |
2-aminopyridines as inhibitors of cyclooxygenase-2
|
RS49982B
(sr)
|
1997-09-17 |
2008-09-29 |
Euro-Celtique S.A., |
Sinergistička analgetička kombinacija analgetičkog opijata i inhibitora ciklooksigenaze-2
|
US6025353A
(en)
*
|
1997-11-19 |
2000-02-15 |
G.D. Searle & Co. |
Method of using cyclooxygenase-2 inhibitors as anti-angiogenic agents
|
US7041694B1
(en)
|
1997-12-17 |
2006-05-09 |
Cornell Research Foundation, Inc. |
Cyclooxygenase-2 inhibition
|
US6375957B1
(en)
|
1997-12-22 |
2002-04-23 |
Euro-Celtique, S.A. |
Opioid agonist/opioid antagonist/acetaminophen combinations
|
AU773642C
(en)
*
|
1997-12-22 |
2006-04-06 |
Mundipharma Pty Limited |
Opioid agonist/antagonist combinations
|
CN1204890C
(zh)
*
|
1997-12-22 |
2005-06-08 |
欧罗赛铁克股份有限公司 |
防止阿片样物质滥用的方法
|
US6887893B1
(en)
*
|
1997-12-24 |
2005-05-03 |
Sankyo Company, Limited |
Methods and compositions for treatment and prevention of tumors, tumor-related disorders and cachexia
|
KR20010074682A
(ko)
*
|
1998-07-09 |
2001-08-09 |
로즈 암스트롱, 크리스틴 에이. 트러트웨인 |
부비동 두통을 완화시키기 위한 gaba 유사체 및충혈제거제를 포함하는 조성물
|
US6858598B1
(en)
|
1998-12-23 |
2005-02-22 |
G. D. Searle & Co. |
Method of using a matrix metalloproteinase inhibitor and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
|
US6649645B1
(en)
*
|
1998-12-23 |
2003-11-18 |
Pharmacia Corporation |
Combination therapy of radiation and a COX-2 inhibitor for treatment of neoplasia
|
US6833373B1
(en)
|
1998-12-23 |
2004-12-21 |
G.D. Searle & Co. |
Method of using an integrin antagonist and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
|
US6376242B1
(en)
*
|
1999-09-21 |
2002-04-23 |
Emory University |
Methods and compositions for treating platelet-related disorders using MPL pathway inhibitory agents
|
IL144760A0
(en)
*
|
1999-12-08 |
2002-06-30 |
Pharmacia Corp |
Cyclooxygenase-2 inhibitor compositions having rapid onset of therapeutic effect
|
EP1246621A4
(de)
*
|
1999-12-23 |
2004-11-24 |
Nitromed Inc |
Nitrosierte und nitrosylierte cyclooxygenase-2-inhibitoren, zusammensetzungen und methoden für deren verwendung
|
PT2092936E
(pt)
|
2000-02-08 |
2013-06-20 |
Euro Celtique Sa |
Formulações orais de agonistas de opióides resistentes a adulteração
|
ES2312413T3
(es)
|
2000-02-08 |
2009-03-01 |
Euro-Celtique S.A. |
Composiciones de liberacion controlada que contienen un agonista y antagonista de opioide.
|
TR200001872A3
(tr)
|
2000-06-26 |
2002-01-21 |
Fako Ilaclari A.S |
4-[5-(4-Metilfenil-3-(triflorometil)-1H-pirazol-1-il] benzensulfonamit' in yeni kristal biçimi "Biçim I" ve bu ürünün üretilmesine iliskin yöntem.
|
EP1299123A2
(de)
*
|
2000-07-13 |
2003-04-09 |
Pharmacia Corporation |
Verwendung von cox-2 hemmern zur behandlung und vorbeugung von cox-2-abhängigen augenkrankheiten
|
PE20020146A1
(es)
*
|
2000-07-13 |
2002-03-31 |
Upjohn Co |
Formulacion oftalmica que comprende un inhibidor de ciclooxigenasa-2 (cox-2)
|
CN100488500C
(zh)
|
2000-07-20 |
2009-05-20 |
劳拉斯有限公司 |
Cox-2抑制剂预防免疫缺陷的用途
|
US6716829B2
(en)
|
2000-07-27 |
2004-04-06 |
Pharmacia Corporation |
Aldosterone antagonist and cyclooxygenase-2 inhibitor combination therapy to prevent or treat inflammation-related cardiovascular disorders
|
WO2002017896A2
(en)
*
|
2000-08-29 |
2002-03-07 |
Peter Van Patten |
Combination for the treatment of migraine comprising a cyclooxygenase-2 inhibitor and acetylsalicylic acid
|
IL145209A0
(en)
|
2000-09-06 |
2002-06-30 |
Pfizer Prod Inc |
Pharmaceutical combinations for the treatment of stroke and traumatic brain injury
|
US7115565B2
(en)
*
|
2001-01-18 |
2006-10-03 |
Pharmacia & Upjohn Company |
Chemotherapeutic microemulsion compositions of paclitaxel with improved oral bioavailability
|
PE20021017A1
(es)
|
2001-04-03 |
2002-11-24 |
Pharmacia Corp |
Composicion parenteral reconstituible
|
ITMI20010733A1
(it)
|
2001-04-05 |
2002-10-05 |
Recordati Chem Pharm |
Uso di inibitori dell'isoenzina cox-2 per il trattamento dell'incontinenza urinaria
|
US20030105144A1
(en)
|
2001-04-17 |
2003-06-05 |
Ping Gao |
Stabilized oral pharmaceutical composition
|
US6673818B2
(en)
|
2001-04-20 |
2004-01-06 |
Pharmacia Corporation |
Fluoro-substituted benzenesulfonyl compounds for the treatment of inflammation
|
UA81224C2
(uk)
|
2001-05-02 |
2007-12-25 |
Euro Celtic S A |
Дозована форма оксикодону та її застосування
|
CA2446550C
(en)
|
2001-05-11 |
2012-03-06 |
Endo Pharmaceuticals, Inc. |
Abuse-resistant controlled-release opioid dosage form
|
DE60230632D1
(de)
*
|
2001-07-18 |
2009-02-12 |
Euro Celtique Sa |
Pharmazeutische kombinationen von oxycodon und naloxon
|
US20030044458A1
(en)
*
|
2001-08-06 |
2003-03-06 |
Curtis Wright |
Oral dosage form comprising a therapeutic agent and an adverse-effect agent
|
US20030068375A1
(en)
|
2001-08-06 |
2003-04-10 |
Curtis Wright |
Pharmaceutical formulation containing gelling agent
|
UA80682C2
(en)
*
|
2001-08-06 |
2007-10-25 |
Pharmacia Corp |
Orally deliverable stabilized oral suspension formulation and process for the incresaing physical stability of thixotropic pharmaceutical composition
|
DE60232417D1
(de)
|
2001-08-06 |
2009-07-02 |
Euro Celtique Sa |
Opioid-agonist-formulierungen mit freisetzbarem und sequestriertem antagonist
|
WO2003013433A2
(en)
|
2001-08-06 |
2003-02-20 |
Euro-Celtique S.A. |
Sequestered antagonist formulations
|
AR038957A1
(es)
|
2001-08-15 |
2005-02-02 |
Pharmacia Corp |
Terapia de combinacion para el tratamiento del cancer
|
CN102813654A
(zh)
|
2002-04-05 |
2012-12-12 |
欧洲凯尔蒂克公司 |
含有羟氢可待酮和烯丙羟吗啡酮的药物制剂
|
JP2005532792A
(ja)
|
2002-04-17 |
2005-11-04 |
ザ クリーブランド クリニック ファウンデーション |
治療薬剤の抗炎症作用および抗酸化作用をモニターするための全身マーカー
|
AU2003215867A1
(en)
*
|
2002-04-22 |
2003-11-03 |
Pfizer Products Inc. |
Indol-2-ones as selective inhibitors of cyclooxygenase-2
|
ES2375181T3
(es)
|
2002-05-09 |
2012-02-27 |
The Brigham And Women's Hospital, Inc. |
1l 1rl-1 como un marcador de enfermedades cardiovasculares.
|
WO2003095623A2
(en)
*
|
2002-05-10 |
2003-11-20 |
The Trustees Of Columbia University In The City Of New York |
Genetically engineered cell lines and systems for propagating varicella zoster virus and methods of use thereof
|
ITMI20021391A1
(it)
|
2002-06-25 |
2003-12-29 |
Nicox Sa |
Nitroderivati di inibitori della cicloossigenasi-2
|
JP2005535642A
(ja)
*
|
2002-06-28 |
2005-11-24 |
ニトロメッド インコーポレーティッド |
オキシムおよび/またはヒドラゾンを含有するニトロソ化および/またはニトロシル化シクロオキシゲナーゼ−2選択的阻害剤、組成物、および使用方法
|
ES2677769T3
(es)
|
2002-09-20 |
2018-08-06 |
Alpharma Pharmaceuticals Llc |
Subunidad secuestrante y composiciones y procedimientos relacionados
|
UA80447C2
(en)
*
|
2002-10-08 |
2007-09-25 |
|
Methods for treating pain by administering nerve growth factor antagonist and opioid analgesic
|
AU2003304238A1
(en)
|
2002-10-08 |
2005-01-13 |
Rinat Neuroscience Corp. |
Methods for treating post-surgical pain by administering an anti-nerve growth factor antagonist antibody and compositions containing the same
|
ZA200502612B
(en)
|
2002-10-08 |
2007-07-25 |
Rinat Neuroscience Corp |
Methods for treating post-surgical pain by administering a nerve crowth factor antagonist and compositions containing the same
|
US7569364B2
(en)
*
|
2002-12-24 |
2009-08-04 |
Pfizer Inc. |
Anti-NGF antibodies and methods using same
|
DK2270048T3
(en)
|
2002-12-24 |
2016-01-18 |
Rinat Neuroscience Corp |
Anti-NGF antibodies and methods for their use
|
US9498530B2
(en)
|
2002-12-24 |
2016-11-22 |
Rinat Neuroscience Corp. |
Methods for treating osteoarthritis pain by administering a nerve growth factor antagonist and compositions containing the same
|
FR2849849B1
(fr)
*
|
2003-01-13 |
2006-08-04 |
Merck Sante Sas |
Nouveaux acides carboxyliques et derives pour le traitement et la prevention du diabete et des dyslipemies
|
US7772188B2
(en)
|
2003-01-28 |
2010-08-10 |
Ironwood Pharmaceuticals, Inc. |
Methods and compositions for the treatment of gastrointestinal disorders
|
EP1594441B1
(de)
|
2003-02-19 |
2010-12-15 |
Rinat Neuroscience Corp. |
Verfahren zur behandlung von schmerzen durch verabreichung eines nervenwachstumsfaktor-antagonisten und eines nsaid und diese enthaltende zusammensetzung
|
MY135852A
(en)
|
2003-04-21 |
2008-07-31 |
Euro Celtique Sa |
Pharmaceutical products
|
JP2007502831A
(ja)
*
|
2003-08-20 |
2007-02-15 |
ニトロメッド インコーポレーティッド |
ニトロソ化およびニトロシル化心血管化合物、組成物、ならびに使用方法
|
CA2536622C
(en)
|
2003-08-29 |
2014-02-11 |
The Brigham And Women's Hospital, Inc. |
Inhibitors of cellular necrosis
|
PL1663229T3
(pl)
|
2003-09-25 |
2010-09-30 |
Euro Celtique Sa |
Farmaceutyczne kombinacje hydrokodonu i naltreksonu
|
WO2005044227A1
(en)
*
|
2003-11-05 |
2005-05-19 |
Glenmark Pharmaceuticals Limited |
Topical pharmaceutical compositions
|
US20050100594A1
(en)
*
|
2003-11-12 |
2005-05-12 |
Nilendu Sen |
Pharmaceutical formulation containing muscle relaxant and COX-II inhibitor
|
ATE546734T1
(de)
|
2003-12-05 |
2012-03-15 |
Cleveland Clinic Foundation |
Risikomarker für eine herzkreislaufkrankheit
|
US7070816B2
(en)
|
2003-12-05 |
2006-07-04 |
New Chapter, Inc. |
Methods for treating prostatic intraepithelial neoplasia with herbal compositions
|
US7067159B2
(en)
|
2003-12-05 |
2006-06-27 |
New Chapter, Inc. |
Methods for treating prostate cancer with herbal compositions
|
US20090131342A1
(en)
*
|
2004-01-22 |
2009-05-21 |
Nitromed, Inc. |
Nitrosated and/or nitrosylated compounds, compositions and methods of use
|
US7763341B2
(en)
|
2004-01-23 |
2010-07-27 |
Century-Board Usa, Llc |
Filled polymer composite and synthetic building material compositions
|
ATE456580T1
(de)
*
|
2004-04-07 |
2010-02-15 |
Rinat Neuroscience Corp |
Verfahren zur schmerzbehandlung in knochenkrebs durch verabreichung eines ngf-antagonisten
|
AU2005247943A1
(en)
|
2004-05-23 |
2005-12-08 |
Gerard M. Housey |
Theramutein modulators
|
EP1604666A1
(de)
*
|
2004-06-08 |
2005-12-14 |
Euro-Celtique S.A. |
Opioide zur Behandlung der chronischen obstruktiven Lungenkrankheit
|
EP3326617A1
(de)
|
2004-06-12 |
2018-05-30 |
Collegium Pharmaceutical, Inc. |
Missbrauchsverhindernde arzneimittelformulierungen
|
KR20070039885A
(ko)
|
2004-07-01 |
2007-04-13 |
머크 앤드 캄파니 인코포레이티드 |
유사분열 키네신 억제제
|
US7622142B2
(en)
|
2004-09-14 |
2009-11-24 |
New Chapter Inc. |
Methods for treating glioblastoma with herbal compositions
|
US8067464B2
(en)
|
2004-10-04 |
2011-11-29 |
Nitromed, Inc. |
Compositions and methods using apocynin compounds and nitric oxide donors
|
EP2927693A1
(de)
|
2004-10-06 |
2015-10-07 |
The Brigham and Women's Hospital |
Relevanz erzielter Niveaus von Markern für systemische Entzündung nach Behandlung
|
EP1814535A4
(de)
*
|
2004-11-08 |
2008-06-04 |
Nitromed Inc |
Nitrosierte und nitrosylierte verbindungen, zusammensetzungen und verfahren zur behandlung von augenkrankheiten
|
CA2595579A1
(en)
*
|
2005-01-21 |
2006-07-27 |
Nitromed, Inc. |
Cardiovascular compounds comprising heterocyclic nitric oxide donor group compositions and methods of use
|
WO2007086884A2
(en)
*
|
2005-02-16 |
2007-08-02 |
Nitromed, Inc. |
Organic nitric oxide donor salts of antimicrobial compounds, compositions and methods of use
|
EP1858863A1
(de)
*
|
2005-02-28 |
2007-11-28 |
Nitromed, Inc. |
Stickstoffmonoxid-verstärkende gruppen enthaltende cardiovaskuläre verbindungen, zusammensetzungen und anwendungsverfahren
|
EP1702558A1
(de)
*
|
2005-02-28 |
2006-09-20 |
Euro-Celtique S.A. |
Verfahren und Vorrichtung zur Darmtätigkeitserfassung
|
US20090215838A1
(en)
*
|
2005-03-09 |
2009-08-27 |
Nitromed, Inc. |
Organic nitric oxide enhancing salts of angiotensin ii antagonists, compositions and methods of use
|
EP1888050B1
(de)
|
2005-05-17 |
2012-03-21 |
Merck Sharp & Dohme Ltd. |
Cis-4-[(4-chlorophenyl)sulfonyl]-4-(2,5-difluorophenyl)cyclohexanepropansäure zur Behandlug von Krebs
|
US8431110B2
(en)
|
2005-05-23 |
2013-04-30 |
Hmi Medical Innovations, Llc. |
Compounds and method of identifying, synthesizing, optimizing and profiling protein modulators
|
EP1883614A4
(de)
*
|
2005-05-23 |
2010-04-14 |
Nicox Sa |
Organische stickoxide verbessernde salze aus nichtsteroiden entzündungshemmenden verbindungen sowie zusammensetzungen und verwendungsverfahren dafür
|
EP1915157A4
(de)
*
|
2005-08-02 |
2010-09-01 |
Nicox Sa |
Stickoxidverstärkende antimikrobielle verbindungen, zusammensetzungen und verwendungsverfahren
|
TW200804345A
(en)
*
|
2005-08-30 |
2008-01-16 |
Novartis Ag |
Substituted benzimidazoles and methods of preparation
|
AU2006299383A1
(en)
*
|
2005-10-04 |
2007-04-12 |
Nitromed, Inc. |
Methods for treating respiratory disorders
|
US8119358B2
(en)
|
2005-10-11 |
2012-02-21 |
Tethys Bioscience, Inc. |
Diabetes-related biomarkers and methods of use thereof
|
WO2007059311A2
(en)
*
|
2005-11-16 |
2007-05-24 |
Nitromed, Inc. |
Furoxan compounds, compositions and methods of use
|
EP1968584A2
(de)
*
|
2005-12-20 |
2008-09-17 |
Nitromed, Inc. |
Stickoxid-verstärkende glutaminsäure-verbindungen, zusammensetzungen und anwendungsverfahren
|
WO2007075542A2
(en)
*
|
2005-12-22 |
2007-07-05 |
Nitromed, Inc. |
Nitric oxide enhancing pyruvate compounds, compositions and methods of use
|
EP1978964A4
(de)
|
2006-01-24 |
2009-12-09 |
Merck & Co Inc |
Jak2-tyrosinkinase-hemmung
|
GB0603041D0
(en)
|
2006-02-15 |
2006-03-29 |
Angeletti P Ist Richerche Bio |
Therapeutic compounds
|
JP5322917B2
(ja)
|
2006-03-15 |
2013-10-23 |
ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッド |
炎症性疾患の診断および処置のためのゲルゾリンの使用
|
CA2647859C
(en)
|
2006-03-29 |
2016-01-05 |
Nitromed, Inc. |
Nitric oxide enhancing prostaglandin compounds, compositions and methods of use
|
WO2007121484A2
(en)
|
2006-04-19 |
2007-10-25 |
Novartis Ag |
6-o-substituted benzoxazole and benzothiazole compounds and methods of inhibiting csf-1r signaling
|
US20080057590A1
(en)
|
2006-06-07 |
2008-03-06 |
Mickey Urdea |
Markers associated with arteriovascular events and methods of use thereof
|
SI2484346T1
(sl)
|
2006-06-19 |
2017-05-31 |
Alpharma Pharmaceuticals Llc |
Farmacevtski sestavki
|
WO2008082730A2
(en)
*
|
2006-09-19 |
2008-07-10 |
Novartis Ag |
Biomarkers of target modulation, efficacy, diagnosis and/or prognosis for raf inhibitors
|
EP2946778A1
(de)
|
2006-09-22 |
2015-11-25 |
Merck Sharp & Dohme Corp. |
Behandlungsverfahren mit verwendung von fettsäuresyntheseinhibitoren
|
US20110218176A1
(en)
|
2006-11-01 |
2011-09-08 |
Barbara Brooke Jennings-Spring |
Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development
|
PL2805945T3
(pl)
|
2007-01-10 |
2019-09-30 |
Msd Italia S.R.L. |
Indazole podstawione grupą amidową jako inhibitory polimerazy poli(adp-rybozy) - (parp)
|
JP2010516679A
(ja)
*
|
2007-01-19 |
2010-05-20 |
マリンクロット インコーポレイテッド |
診断用および治療用シクロオキシゲナーゼ−2結合リガンド
|
KR101514853B1
(ko)
|
2007-03-01 |
2015-04-24 |
노파르티스 아게 |
Pim 키나제 억제제 및 이들의 사용 방법
|
EP2147315B1
(de)
|
2007-04-18 |
2013-06-26 |
Tethys Bioscience, Inc. |
Biomarker in verbindung mit diabetes und verwendungsverfahren dafür
|
MX2009012679A
(es)
|
2007-05-21 |
2009-12-11 |
Novartis Ag |
Inhibidores de csf-1r, composiciones y metodos de uso.
|
CA2690191C
(en)
|
2007-06-27 |
2015-07-28 |
Merck Sharp & Dohme Corp. |
4-carboxybenzylamino derivatives as histone deacetylase inhibitors
|
JP5411141B2
(ja)
|
2007-09-10 |
2014-02-12 |
カルシメディカ,インク. |
細胞内カルシウムを調節する化合物
|
US8623418B2
(en)
*
|
2007-12-17 |
2014-01-07 |
Alpharma Pharmaceuticals Llc |
Pharmaceutical composition
|
US20100151014A1
(en)
*
|
2008-12-16 |
2010-06-17 |
Alpharma Pharmaceuticals, Llc |
Pharmaceutical composition
|
EP2224808A4
(de)
*
|
2007-12-17 |
2013-11-27 |
Alpharma Pharmaceuticals Llc |
Pharmazeutische zusammensetzung
|
EP2247185B1
(de)
|
2008-03-03 |
2014-04-16 |
Tiger Pharmatech |
Tyrosinkinase-hemmer
|
GB2460915B
(en)
|
2008-06-16 |
2011-05-25 |
Biovascular Inc |
Controlled release compositions of agents that reduce circulating levels of platelets and methods therefor
|
RU2478388C2
(ru)
*
|
2008-07-07 |
2013-04-10 |
Еуро-Селтик С.А. |
Фармацевтическая композиция, содержащая опиоидный антагонист, для лечения задержки мочи
|
MX2011002149A
(es)
|
2008-08-27 |
2011-04-05 |
Calcimedica Inc |
Compuestos que modulan el calcio intracelular.
|
US20100160351A1
(en)
*
|
2008-12-19 |
2010-06-24 |
Nuon Therapeutics, Inc. |
Pharmaceutical compositions and methods for treating hyperuricemia and related disorders
|
WO2010071865A1
(en)
|
2008-12-19 |
2010-06-24 |
Nuon Therapeutics, Inc. |
Pharmaceutical compositions and methods for treating hyperuricemia and related disorders
|
SI2405915T1
(sl)
|
2009-03-10 |
2019-03-29 |
Euro-Celtique S.A. |
Farmacevtski sestavki s takojšnjim sproščanjem, ki vsebujejo oksikodon in nalokson
|
WO2011032175A1
(en)
|
2009-09-14 |
2011-03-17 |
Nuon Therapeutics, Inc. |
Combination formulations of tranilast and allopurinol and methods related thereto
|
WO2011046771A1
(en)
|
2009-10-14 |
2011-04-21 |
Schering Corporation |
SUBSTITUTED PIPERIDINES THAT INCREASE p53 ACTIVITY AND THE USES THEREOF
|
US10668060B2
(en)
|
2009-12-10 |
2020-06-02 |
Collegium Pharmaceutical, Inc. |
Tamper-resistant pharmaceutical compositions of opioids and other drugs
|
AU2011210508B2
(en)
|
2010-02-01 |
2015-01-29 |
The Hospital For Sick Children |
Remote ischemic conditioning for treatment and prevention of restenosis
|
EP2552331B1
(de)
|
2010-03-31 |
2020-01-08 |
The Hospital For Sick Children |
Verwendung ischämischer remote-konditionierungen zur verbesserung der ergebnisse nach myokardinfarkten
|
JP6112486B2
(ja)
|
2010-04-27 |
2017-04-12 |
カルシメディカ,インク. |
細胞内カルシウムを調節する化合物
|
EP2563759B1
(de)
|
2010-04-27 |
2022-04-06 |
Calcimedica, Inc. |
Verbindungen als modulatoren von intrazellulärem calcium
|
EP2584903B1
(de)
|
2010-06-24 |
2018-10-24 |
Merck Sharp & Dohme Corp. |
Neue heterozyklische verbindungen als erk-hemmer
|
JP6043285B2
(ja)
|
2010-08-02 |
2016-12-14 |
サーナ・セラピューティクス・インコーポレイテッドSirna Therapeutics,Inc. |
低分子干渉核酸(siNA)を用いたカテニン(カドヘリン結合型タンパク質)β1(CTNNB1)遺伝子発現のRNA干渉媒介性阻害
|
LT2606134T
(lt)
|
2010-08-17 |
2019-07-25 |
Sirna Therapeutics, Inc. |
Hepatito b viruso (hbv) geno raiškos slopinimas, tarpininkaujant rnr interferencijai naudojant mažą interferuojančią nukleorūgštį (sina)
|
EP3333188B1
(de)
|
2010-08-19 |
2022-02-09 |
Zoetis Belgium S.A. |
Anti-ngf-antikörper und deren verwendung
|
EP2608669B1
(de)
|
2010-08-23 |
2016-06-22 |
Merck Sharp & Dohme Corp. |
Neue pyrazolo-[1,5-a-]pyrimidinderivate als mtor-hemmer
|
US9079891B2
(en)
|
2010-08-27 |
2015-07-14 |
Calcimedica, Inc. |
Compounds that modulate intracellular calcium
|
US8946216B2
(en)
|
2010-09-01 |
2015-02-03 |
Merck Sharp & Dohme Corp. |
Indazole derivatives useful as ERK inhibitors
|
EP2615916B1
(de)
|
2010-09-16 |
2017-01-04 |
Merck Sharp & Dohme Corp. |
Kondensierte pyrazolderivate als neue erk-hemmer
|
US9260471B2
(en)
|
2010-10-29 |
2016-02-16 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of gene expression using short interfering nucleic acids (siNA)
|
WO2012087772A1
(en)
|
2010-12-21 |
2012-06-28 |
Schering Corporation |
Indazole derivatives useful as erk inhibitors
|
CN104873455B
(zh)
|
2010-12-22 |
2023-09-12 |
普渡制药公司 |
包覆的抗篡改控制释放剂型
|
US9233073B2
(en)
|
2010-12-23 |
2016-01-12 |
Purdue Pharma L.P. |
Tamper resistant solid oral dosage forms
|
CA2831730A1
(en)
|
2011-04-21 |
2012-10-26 |
Piramal Enterprises Limited |
A crystalline form of a salt of a morpholino sulfonyl indole derivative and a process for its preparation
|
HUE055505T2
(hu)
|
2011-05-20 |
2021-11-29 |
H Lundbeck As |
Anti-CGRP készítmények és alkalmazásuk
|
WO2013063214A1
(en)
|
2011-10-27 |
2013-05-02 |
Merck Sharp & Dohme Corp. |
Novel compounds that are erk inhibitors
|
EP2773207B1
(de)
|
2011-10-31 |
2018-03-07 |
Merck Sharp & Dohme Corp. |
Aminopyrimidinone als interleukinrezeptor-assoziierte kinaseinhibitoren
|
US20150299696A1
(en)
|
2012-05-02 |
2015-10-22 |
Sirna Therapeutics, Inc. |
SHORT INTERFERING NUCLEIC ACID (siNA) COMPOSITIONS
|
NZ728724A
(en)
|
2012-05-11 |
2018-03-23 |
Reset Therapeutics Inc |
Carbazole-containing sulfonamides as cryptochrome modulators
|
US9617334B2
(en)
|
2012-06-06 |
2017-04-11 |
Zoetis Services Llc |
Caninized anti-NGF antibodies and methods thereof
|
CN105050598B
(zh)
|
2012-09-28 |
2018-04-27 |
默沙东公司 |
作为erk抑制剂的新型化合物
|
WO2014059333A1
(en)
|
2012-10-12 |
2014-04-17 |
Calcimedica, Inc. |
Compounds that modulate intracellular calcium
|
RU2660349C2
(ru)
|
2012-11-28 |
2018-07-05 |
Мерк Шарп И Доум Корп. |
Композиции и способы для лечения злокачественной опухоли
|
WO2014100065A1
(en)
|
2012-12-20 |
2014-06-26 |
Merck Sharp & Dohme Corp. |
Substituted imidazopyridines as hdm2 inhibitors
|
EP2951180B1
(de)
|
2013-01-30 |
2018-05-02 |
Merck Sharp & Dohme Corp. |
2,6,7,8-substituierte purine als hdm2-inhibitoren
|
EA201500742A1
(ru)
|
2013-02-05 |
2015-12-30 |
Пердью Фарма Л.П. |
Защищенные от нецелевого использования фармацевтические композиции
|
US10751287B2
(en)
|
2013-03-15 |
2020-08-25 |
Purdue Pharma L.P. |
Tamper resistant pharmaceutical formulations
|
US20160166576A1
(en)
|
2013-07-11 |
2016-06-16 |
Merck Sharp & Dohme Corp. |
Substituted amidopyrazole inhibitors of interleukin receptor-associated kinases (irak-4)
|
JP2016525138A
(ja)
|
2013-07-23 |
2016-08-22 |
ユーロ−セルティーク エス.エイ. |
疼痛および腸内ディスバイオシスをもたらす疾患および/または腸内細菌移行に対するリスクを高める疾患に罹患している患者における痛みの治療への使用のためのオキシコドンおよびナロキソンの組み合わせ
|
US20160194368A1
(en)
|
2013-09-03 |
2016-07-07 |
Moderna Therapeutics, Inc. |
Circular polynucleotides
|
US9611263B2
(en)
|
2013-10-08 |
2017-04-04 |
Calcimedica, Inc. |
Compounds that modulate intracellular calcium
|
TWI690521B
(zh)
|
2014-04-07 |
2020-04-11 |
美商同步製藥公司 |
作為隱花色素調節劑之含有咔唑之醯胺類、胺基甲酸酯類及脲類
|
JO3589B1
(ar)
|
2014-08-06 |
2020-07-05 |
Novartis Ag |
مثبطات كيناز البروتين c وطرق استخداماتها
|
WO2016144849A1
(en)
|
2015-03-12 |
2016-09-15 |
Merck Sharp & Dohme Corp. |
Thienopyrazine inhibitors of irak4 activity
|
US10155765B2
(en)
|
2015-03-12 |
2018-12-18 |
Merck Sharp & Dohme Corp. |
Carboxamide inhibitors of IRAK4 activity
|
EP3267996B1
(de)
|
2015-03-12 |
2020-11-11 |
Merck Sharp & Dohme Corp. |
Pyrazolopyrimidinhibitoren der irak4-aktivität
|
EP3292213A1
(de)
|
2015-05-04 |
2018-03-14 |
Academisch Medisch Centrum |
Biomarker für den nachweis von aspirinunempfindlichkeit
|
TWI770020B
(zh)
|
2016-04-15 |
2022-07-11 |
丹麥商H朗德貝克公司 |
人類化抗pacap 抗體及其用途
|
WO2017222575A1
(en)
|
2016-06-23 |
2017-12-28 |
Collegium Pharmaceutical, Inc. |
Process of making more stable abuse-deterrent oral formulations
|
US10947234B2
(en)
|
2017-11-08 |
2021-03-16 |
Merck Sharp & Dohme Corp. |
PRMT5 inhibitors
|
US10982002B2
(en)
|
2018-03-12 |
2021-04-20 |
Zoetis Services Llc |
Anti-NGF antibodies and methods thereof
|
US20210309688A1
(en)
|
2018-08-07 |
2021-10-07 |
Merck Sharp & Dohme Corp. |
Prmt5 inhibitors
|
WO2020033282A1
(en)
|
2018-08-07 |
2020-02-13 |
Merck Sharp & Dohme Corp. |
Prmt5 inhibitors
|
MA53650A
(fr)
|
2018-09-19 |
2021-07-28 |
Modernatx Inc |
Lipides peg et leurs utilisations
|
CA3113353A1
(en)
|
2018-09-19 |
2020-03-26 |
Modernatx, Inc. |
High-purity peg lipids and uses thereof
|
CN112624943B
(zh)
*
|
2020-12-28 |
2022-07-01 |
成都伊诺达博医药科技有限公司 |
一种非罗考昔中间体的合成方法
|
IL305573A
(en)
|
2021-03-15 |
2023-10-01 |
Saul Yedgar |
Hyaluronic acid conjugated with dipalmitoyl phosphatidyl ethanolamine in combination with non-steroidal anti-inflammatory drugs (NSAIDs) for the treatment or suppression of inflammatory diseases
|
CA3229059A1
(en)
|
2021-08-27 |
2023-03-02 |
H. Lundbeck A/S |
Treatment of cluster headache using anti-cgrp antibodies
|